Table I.
Clinical information for 20% of patients with longer survival times in low-survivin expression group.
| Sample ID | Gender | Age, years | OS, days | TCGA subtype | IDH mutation | MGMT methylation | RT | TMZ | TP53 mutation | EGFR mutation | ATRX mutation |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 494 | F | 59 | 2,072 | Neural | 0 | 1 | 1 | 1 | 1 | 0 | 0 |
| 680 | M | 44 | 1,832 | Neural | 0 | 0 | 1 | 1 | 1 | 0 | 0 |
| 761 | M | 45 | 1,744 | Proneural | 1 | 1 | 1 | 0 | 0 | 1 | 0 |
| 822 | M | 46 | 1,324 | Proneural | 1 | 1 | 1 | 1 | 1 | 0 | 0 |
| 491 | F | 37 | 1,074 | Proneural | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| D37 | M | 55 | 965 | Mesenchymal | 0 | 0 | 1 | 1 | 1 | 0 | 0 |
| 1026 | M | 59 | 875 | Classical | 0 | 1 | 1 | 1 | 0 | 0 | 0 |
| D57 | M | 40 | 766 | Classical | 0 | NA | 1 | 1 | 1 | 0 | 0 |
| 802 | M | 43 | 681 | Mesenchymal | 0 | 0 | 1 | 1 | 1 | 0 | 0 |
| 1023 | F | 58 | 681 | Classical | 0 | 0 | NA | NA | 0 | 0 | 0 |
| 700 | F | 25 | 669 | Proneural | 0 | 1 | 1 | 1 | 0 | 0 | 0 |
| D35 | F | 68 | 661 | Mesenchymal | 0 | 1 | 1 | 0 | 1 | 0 | 1 |
| 710 | M | 42 | 660 | Mesenchymal | 1 | 1 | 0 | 1 | 0 | 0 | 0 |
F, female; M, male; OS, overall survival; TCGA, the cancer genome atlas; IDH, isocitrate dehydrogenase; MGMT, O6-alkylguanine DNA alkyltransferase; RT, radiotherapy; TMZ, temozolomide; TP53, tumor suppressor p53; EGFR, epidermal growth factor receptor; 0, no; 1, yes; NA, not available.